{"links":{"feed":"https://www.erudio.com/reports/bgb-11417-101-nct04277637/feed.json","html":"https://www.erudio.com/reports/bgb-11417-101-nct04277637","json":"https://www.erudio.com/reports/bgb-11417-101-nct04277637.json","markdown":"https://www.erudio.com/reports/bgb-11417-101-nct04277637.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"bgb-11417-101-nct04277637"}},"request":"https://www.erudio.com/contact?report=bgb-11417-101-nct04277637"},"offer":{"cited_clinicians":6,"cited_commentary_sources":27,"verified_hcp_statements":133,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":9},"for_sale":true,"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"bgb-11417-101-nct04277637"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=bgb-11417-101-nct04277637","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/bgb-11417-101-nct04277637","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 133 verified statements · 68 from 6 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-20T01:21:22.957941Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":16,"no_commentary_found":1},"aspects":[{"claim_count":19,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":12,"title":"Primary endpoint: Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":0,"title":"Primary endpoint: Number of Participants Experiencing Serious Adverse Events (SAEs)"},{"claim_count":6,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.primaryOutcomes[2]","source_count":5,"title":"Primary endpoint: Number of Participants Experiencing Adverse Events (AEs) leading to discontinuation of Sonrotoclax"},{"claim_count":3,"coverage":"discussed","id":"T4","registry_field":"outcomesModule.primaryOutcomes[3]","source_count":3,"title":"Primary endpoint: Part 1, Part 3: Maximum Tolerated Dose (MTD) of Sonrotoclax"},{"claim_count":5,"coverage":"discussed","id":"T5","registry_field":"outcomesModule.primaryOutcomes[4]","source_count":5,"title":"Primary endpoint: Part 1, Part 3, Part 5: RP2D of Sonrotoclax"},{"claim_count":15,"coverage":"discussed","id":"T6","registry_field":"outcomesModule.primaryOutcomes[5]","source_count":11,"title":"Primary endpoint: Part 1, Part 3, Part 5: Number of participants experiencing tumor lysis syndrome (TLS) relevant events"},{"claim_count":2,"coverage":"discussed","id":"T7","registry_field":"outcomesModule.primaryOutcomes[6]","source_count":2,"title":"Primary endpoint: Part 1, Part 3, Part 5: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs"},{"claim_count":4,"coverage":"discussed","id":"T8","registry_field":"outcomesModule.secondaryOutcomes","source_count":4,"title":"Secondary endpoints"},{"claim_count":16,"coverage":"discussed","id":"T9","registry_field":"conditionsModule","source_count":10,"title":"Population and setting"},{"claim_count":26,"coverage":"discussed","id":"T10","registry_field":"armsInterventionsModule.armGroups","source_count":16,"title":"The comparison"},{"claim_count":30,"coverage":"discussed","id":"T11","registry_field":"outcomesModule","source_count":16,"title":"Safety and tolerability"},{"claim_count":19,"coverage":"discussed","id":"T12","registry_field":"designModule","source_count":8,"title":"Design and conduct"},{"claim_count":36,"coverage":"discussed","id":"A1","source_count":16,"title":"How speakers interpret MRD depth, response and durability"},{"claim_count":14,"coverage":"discussed","id":"A2","source_count":5,"title":"Finite therapy, continuous BTK inhibition and patient burden"},{"claim_count":21,"coverage":"discussed","id":"A3","source_count":14,"title":"Pharmacologic differentiation, resistance hypotheses and escalation opportunities"},{"claim_count":19,"coverage":"discussed","id":"A4","source_count":10,"title":"Histology-specific activity and reasons for further development"},{"claim_count":25,"coverage":"discussed","id":"A5","source_count":21,"title":"Research enrollment, validation needs and strength of endorsement"}],"counts":{"cited_clinicians":6,"cited_clinicians_by_role":{"physician":3,"physician, Hematology":1,"physician, Medical oncology":2},"cited_physicians":6,"cited_sources":27,"claims_by_expression_type":{"comparison":18,"experience":3,"interpretation":53,"opinion":20,"restatement":23,"uncertainty":6,"unspecified":10},"claims_by_kind":{"source_observation":133},"clinician_statements":68,"evidence_units":51,"findings":13,"organisational_accounts":1,"people_cited":11,"people_identity_verified":9,"people_total":11,"screened_sources":55,"verified_claims":133},"findings_index":[{"cited_clinicians":1,"id":"F1","structure":{"claims":11,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":1,"views":7},"limitations":2,"links":{"context":2,"support":11},"ma_question":true,"named_voices":2,"passages":6,"sources":4,"sources_by_kind":{"media":4}},"title":"CLL MRD depth: what speakers highlight without settling its clinical meaning","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-f29fd1547bd6023cc8fe","claim-ffb4ad5fb389e721c89f","claim-b7acea4127807bc7f1cc","claim-a36fc800bcaeb84cfc30","claim-43d6d399039d06422047","claim-36365e4f86f1ee030933"],"clause":"without settling its clinical meaning","holders":2},"cited_claim_ids":["claim-f29fd1547bd6023cc8fe","claim-d9cf7541439343bf7d79","claim-a36fc800bcaeb84cfc30","claim-3bc608b731526c2b5286","claim-43d6d399039d06422047"],"clinicians":false,"holders":2,"speakers":2,"view":"reading"},"evidence_line":"11 statements from 2 speakers in 4 sources, all podcasts or videos","holder_line":"2 of the 2 named speakers in this finding hold this view; 2 of them hold its caveat, “without settling its clinical meaning”"},{"cited_clinicians":2,"id":"F2","structure":{"claims":18,"claims_by_group":{"comparisons":9,"experience":1,"questions":1,"restated":1,"views":6},"limitations":3,"links":{"context":2,"support":18},"ma_question":true,"named_voices":4,"passages":12,"sources":9,"sources_by_kind":{"media":9}},"title":"CLL doublets: why some speakers foresee possible replacement of ibrutinib–venetoclax","title_holders":{"cited_claim_ids":["claim-fff17d03935be5bb2b8d","claim-51abc372db3268b34e99"],"clinicians":false,"holders":2,"speakers":4,"view":"reading"},"evidence_line":"18 statements from 4 speakers in 9 sources, all podcasts or videos","holder_line":"2 of the 4 named speakers in this finding hold this view"},{"cited_clinicians":0,"id":"F3","structure":{"claims":6,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":0,"views":3},"limitations":3,"links":{"context":0,"support":7},"ma_question":true,"named_voices":1,"passages":3,"sources":1,"sources_by_kind":{"media":1}},"title":"CLL: a speaker favors finite therapy but retains a continuous BTKi option","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-d97722cd6ce7c9855655"],"clause":"retain a continuous BTKi option","holders":1},"cited_claim_ids":["claim-9498a98d7ff4e5aaac63","claim-d97722cd6ce7c9855655"],"clinicians":false,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"6 statements from 1 speaker in 1 source, a podcast or video","holder_line":"The one named speaker in this finding holds this view; 1 of them holds its caveat, “retain a continuous BTKi option”"},{"cited_clinicians":2,"id":"F4","structure":{"claims":15,"claims_by_group":{"comparisons":4,"experience":0,"questions":0,"restated":4,"views":7},"limitations":3,"links":{"context":2,"support":17},"ma_question":true,"named_voices":3,"passages":12,"sources":9,"sources_by_kind":{"commentary":2,"media":7}},"title":"CLL doublet: how most speakers weigh tolerability against neutropenia and infections","title_holders":{"cited_claim_ids":["claim-04f1982ddeb65207255e","claim-e1d9cc4742830a17bf34","claim-427efbde2f147aa83082","claim-e533d98b48792be0ce80","claim-12dc065f23ad9830fa35","claim-cb8037844c5551578625","claim-267bd6307384a13d115c","claim-cb3b521d925dfc9625a8","claim-97b79910fb7f019f3efe","claim-b53397e540a489428244"],"clinicians":false,"holders":2,"speakers":3,"view":"reading"},"evidence_line":"15 statements from 3 speakers in 9 sources, 7 of them podcasts or videos","holder_line":"2 of the 3 named speakers in this finding hold this view"},{"cited_clinicians":1,"id":"F5","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":3,"views":2},"limitations":2,"links":{"context":0,"support":5},"ma_question":true,"named_voices":2,"passages":5,"sources":4,"sources_by_kind":{"media":4}},"title":"320-mg sonrotoclax: why a speaker sees an efficacy–tolerability balance, not an MTD","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-1e56f80fe1a396f3da10","claim-e77c09eacfbb31686675","claim-826cdca44ad0c7b38a6b"],"clause":"not an MTD","holders":2},"cited_claim_ids":["claim-1e56f80fe1a396f3da10"],"clinicians":false,"holders":1,"speakers":2,"view":"reading"},"evidence_line":"5 statements from 2 speakers in 4 sources, all podcasts or videos","holder_line":"1 of the 2 named speakers in this finding holds this view; 2 of the 2 hold its caveat, “not an MTD”"},{"cited_clinicians":1,"id":"F6","structure":{"claims":9,"claims_by_group":{"comparisons":3,"experience":0,"questions":0,"restated":2,"views":4},"limitations":3,"links":{"context":0,"support":10},"ma_question":true,"named_voices":3,"passages":9,"sources":7,"sources_by_kind":{"media":7}},"title":"Ramp-up: a speaker eyes shortening after study; a clinician values outpatient use","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-5ad2b75b5a275864ad81"],"clause":"a clinician values outpatient use","holders":1},"cited_claim_ids":["claim-c6a26dd737b5ca6e7881","claim-e7d10a84bc8098d63538"],"clinicians":false,"holders":1,"speakers":3,"view":"reading"},"evidence_line":"9 statements from 3 speakers in 7 sources, all podcasts or videos","holder_line":"1 of the 3 named speakers in this finding holds this view; 1 of the 3 holds its caveat, “a clinician values outpatient use”"},{"cited_clinicians":1,"id":"F7","structure":{"claims":16,"claims_by_group":{"comparisons":2,"experience":0,"questions":0,"restated":5,"views":9},"limitations":3,"links":{"context":0,"support":18},"ma_question":true,"named_voices":1,"passages":4,"sources":2,"sources_by_kind":{"media":2}},"title":"R/R CLL: a clinician highlights MRD depth but leaves time off treatment unspecified","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-ce328db5d3bfa3f2a0fa"],"clause":"leave time off treatment unspecified","holders":1},"cited_claim_ids":["claim-708e2182699b02bc6819","claim-00789045a672a294acc6"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"16 statements from 1 speaker in 2 sources, all podcasts or videos","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician; 1 of them holds its caveat, “leave time off treatment unspecified”"},{"cited_clinicians":1,"id":"F8","structure":{"claims":16,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":4,"views":12},"limitations":2,"links":{"context":3,"support":19},"ma_question":true,"named_voices":3,"passages":8,"sources":5,"sources_by_kind":{"commentary":3,"media":2}},"title":"First-line CLL: what speakers highlight in response rates and uMRD","title_holders":{"cited_claim_ids":["claim-f841b7b86e3a225d9fe7","claim-e1c12f4baab0954b20da","claim-e5f7a7b4875eb28f3581","claim-c5cea16607c89d79e385","claim-5d582fe26ff817fe4869","claim-bec3b5323ebbd8509c43","claim-d4b5885a4c60f08f655b","claim-b95cc210e7a7212c9646"],"clinicians":false,"holders":3,"speakers":3,"view":"reading"},"evidence_line":"16 statements from 3 speakers in 5 sources, 2 of them podcasts or videos","holder_line":"3 of the 3 named speakers in this finding hold this view"},{"cited_clinicians":2,"id":"F9","structure":{"claims":8,"claims_by_group":{"comparisons":1,"experience":1,"questions":1,"restated":2,"views":3},"limitations":3,"links":{"context":0,"support":8},"ma_question":true,"named_voices":2,"passages":2,"sources":2,"sources_by_kind":{"commentary":1,"media":1}},"title":"Sonrotoclax–obinutuzumab: a clinician sees MRD-led stops; one awaits an RCT","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-72af0e42bb6cfe7a8496","claim-1be31ed310e92b03010e"],"clause":"one awaits an RCT","holders":1},"cited_claim_ids":["claim-7b0821ca99b0eb5c2519","claim-aa9635811004ac29b71f"],"clinicians":true,"holders":1,"speakers":2,"view":"reading"},"evidence_line":"8 statements from 2 speakers in 2 sources, 1 of them a podcast or video","holder_line":"1 of the 2 named speakers in this finding holds this view, a confirmed clinician; 1 of the 2 holds its caveat, “one awaits an RCT”"},{"cited_clinicians":1,"id":"F10","structure":{"claims":12,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":7,"views":4},"limitations":4,"links":{"context":0,"support":16},"ma_question":true,"named_voices":1,"passages":3,"sources":1,"sources_by_kind":{"media":1}},"title":"CLL triplet: what a clinician highlights in early off-treatment remission","title_holders":{"cited_claim_ids":["claim-691203934121c65034a1","claim-202026914e48d9160cc4","claim-8bc5227cd7772de0fcc2"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"12 statements from 1 speaker in 1 source, a podcast or video","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician"},{"cited_clinicians":1,"id":"F11","structure":{"claims":6,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":1,"views":4},"limitations":3,"links":{"context":0,"support":6},"ma_question":true,"named_voices":2,"passages":4,"sources":4,"sources_by_kind":{"commentary":2,"media":2}},"title":"Sonrotoclax in MCL: where speakers split on how far early findings go","title_holders":{"cited_claim_ids":["claim-4bd3a463b5058779ec9e","claim-0cdde999a4ba124f9f78"],"clinicians":false,"holders":2,"sides":[{"cited_claim_ids":["claim-4bd3a463b5058779ec9e"],"holders":1},{"cited_claim_ids":["claim-0cdde999a4ba124f9f78"],"holders":1}],"speakers":2,"view":"split"},"evidence_line":"6 statements from 2 speakers in 4 sources, 2 of them podcasts or videos","holder_line":"2 of the 2 named speakers in this finding take a side on this question: 1 on one side, 1 on the other"},{"cited_clinicians":2,"id":"F12","structure":{"claims":9,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":2,"views":6},"limitations":3,"links":{"context":0,"support":9},"ma_question":true,"named_voices":3,"passages":3,"sources":3,"sources_by_kind":{"commentary":1,"media":2}},"title":"Sonrotoclax in WM: why most speakers see phase 1 as grounds for further study","title_holders":{"cited_claim_ids":["claim-dd098095db7fd1fa5e5f","claim-a4b6282a12c561217979","claim-4284d8ea6f2289ba06a8","claim-ac0f359ac1e46343f751"],"clinicians":false,"holders":2,"speakers":3,"view":"reading"},"evidence_line":"9 statements from 3 speakers in 3 sources, 2 of them podcasts or videos","holder_line":"2 of the 3 named speakers in this finding hold this view"},{"cited_clinicians":1,"id":"F13","structure":{"claims":11,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":3,"views":7},"limitations":2,"links":{"context":1,"support":16},"ma_question":true,"named_voices":2,"passages":6,"sources":4,"sources_by_kind":{"media":4}},"title":"Phase 1 sonrotoclax: a clinician tempers DLBCL hopes but favors CLL combination study","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-6f25466b533700831d2a"],"clause":"favor CLL combination study","holders":1},"cited_claim_ids":["claim-f73f3348d3ca4a741401","claim-05f45cd0ab53af9eecf8","claim-dfdf2f8389ee219e6f24"],"clinicians":true,"holders":1,"speakers":2,"view":"reading"},"evidence_line":"11 statements from 2 speakers in 4 sources, all podcasts or videos","holder_line":"1 of the 2 named speakers in this finding holds this view, a confirmed clinician; 1 of them holds its caveat, “favor CLL combination study”"}],"open_question":{"basis":"From finding F1 (11 statements from 2 speakers in 4 sources)","cited_claim_ids":["claim-f29fd1547bd6023cc8fe","claim-f8901030dc9dff54be08","claim-d9cf7541439343bf7d79","claim-ffb4ad5fb389e721c89f","claim-b7acea4127807bc7f1cc","claim-a36fc800bcaeb84cfc30","claim-36b959ed1f47d068b657","claim-ca1db305da310528851d","claim-3bc608b731526c2b5286","claim-43d6d399039d06422047","claim-36365e4f86f1ee030933"],"finding_ids":["F1"],"question":"What do clinicians say they need to see from longer follow-up of sonrotoclax plus zanubrutinib in CLL to determine whether undetectable MRD translates into prolonged PFS?"},"sections":{"analysis":[{"id":"section-1","level":3,"title":"Speakers welcome deep MRD responses but leave their longer-term clinical meaning unresolved"},{"id":"section-2","level":3,"title":"Two speakers foresee possible replacement of ibrutinib–venetoclax, emphasizing different advantages"},{"id":"section-3","level":3,"title":"One speaker favors finite CLL treatment while preserving continuous BTK inhibition for some patients"},{"id":"section-4","level":3,"title":"Speakers regard the CLL doublet as tolerable while retaining neutropenia and infection qualifications"},{"id":"section-5","level":3,"title":"One speaker reads 320 mg as an efficacy–tolerability compromise rather than a toxicity ceiling"},{"id":"section-6","level":3,"title":"One speaker anticipates shorter step-ups; another values movement toward outpatient initiation"},{"id":"section-7","level":3,"title":"Whether remission persists after elective stopping of the relapsed/refractory CLL doublet"},{"id":"section-8","level":3,"title":"One speaker sees first-line all-oral, MRD-driven treatment as a direction to watch, including in high-risk CLL"},{"id":"section-9","level":3,"title":"One speaker highlights MRD-guided stopping with sonrotoclax–obinutuzumab; an account seeks randomized confirmation"},{"id":"section-10","level":3,"title":"One speaker sees potential for durable off-treatment remission with the CLL triplet"},{"id":"section-11","level":3,"title":"One speaker stresses immature MCL combination evidence despite enthusiasm; an X account calls sonrotoclax a “major advance”"},{"id":"section-12","level":3,"title":"Two speakers view the WM experience as a reason for further study"},{"id":"section-13","level":3,"title":"One speaker tempers broad activity expectations in DLBCL and favors combination development"},{"id":"section-14","level":3,"title":"Scope and coverage of the sources reviewed"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, non randomized, parallel, phase1","trial_dimensions":[{"findings":[{"id":"F4","shared_claims":11},{"id":"F6","shared_claims":1},{"id":"F7","shared_claims":3},{"id":"F9","shared_claims":4},{"id":"F10","shared_claims":2},{"id":"F12","shared_claims":1},{"id":"F13","shared_claims":2}],"id":"T1","label":"Primary endpoint: Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)"},{"findings":[],"id":"T2","label":"Primary endpoint: Number of Participants Experiencing Serious Adverse Events (SAEs)"},{"findings":[{"id":"F4","shared_claims":1},{"id":"F9","shared_claims":3},{"id":"F10","shared_claims":1},{"id":"F12","shared_claims":1}],"id":"T3","label":"Primary endpoint: Number of Participants Experiencing Adverse Events (AEs) leading to discontinuation of Sonrotoclax"},{"findings":[{"id":"F5","shared_claims":3},{"id":"F7","shared_claims":1}],"id":"T4","label":"Primary endpoint: Part 1, Part 3: Maximum Tolerated Dose (MTD) of Sonrotoclax"},{"findings":[{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":3},{"id":"F7","shared_claims":1},{"id":"F10","shared_claims":1},{"id":"F13","shared_claims":1}],"id":"T5","label":"Primary endpoint: Part 1, Part 3, Part 5: RP2D of Sonrotoclax"},{"findings":[{"id":"F4","shared_claims":3},{"id":"F6","shared_claims":5},{"id":"F7","shared_claims":1},{"id":"F8","shared_claims":2},{"id":"F9","shared_claims":3},{"id":"F10","shared_claims":2},{"id":"F12","shared_claims":1},{"id":"F13","shared_claims":1}],"id":"T6","label":"Primary endpoint: Part 1, Part 3, Part 5: Number of participants experiencing tumor lysis syndrome (TLS) relevant events"},{"findings":[{"id":"F5","shared_claims":2}],"id":"T7","label":"Primary endpoint: Part 1, Part 3, Part 5: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs"},{"findings":[{"id":"F2","shared_claims":2},{"id":"F6","shared_claims":3},{"id":"F10","shared_claims":1}],"id":"T8","label":"Secondary endpoints"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":2},{"id":"F6","shared_claims":1},{"id":"F7","shared_claims":3},{"id":"F8","shared_claims":1},{"id":"F10","shared_claims":3},{"id":"F11","shared_claims":1},{"id":"F12","shared_claims":1},{"id":"F13","shared_claims":1}],"id":"T9","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":8},{"id":"F3","shared_claims":2},{"id":"F7","shared_claims":1},{"id":"F8","shared_claims":3},{"id":"F9","shared_claims":3},{"id":"F10","shared_claims":3},{"id":"F12","shared_claims":1},{"id":"F13","shared_claims":2}],"id":"T10","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":2},{"id":"F4","shared_claims":12},{"id":"F6","shared_claims":4},{"id":"F7","shared_claims":4},{"id":"F8","shared_claims":2},{"id":"F9","shared_claims":2},{"id":"F10","shared_claims":3},{"id":"F11","shared_claims":2},{"id":"F12","shared_claims":1},{"id":"F13","shared_claims":3}],"id":"T11","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F3","shared_claims":1},{"id":"F5","shared_claims":3},{"id":"F6","shared_claims":2},{"id":"F7","shared_claims":3},{"id":"F9","shared_claims":2},{"id":"F10","shared_claims":6},{"id":"F13","shared_claims":2}],"id":"T12","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-20T01:21:22.957941Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-20T04:56:14Z","record_hash":"5d4952af08c834bd3b29db046f0e5d84763c354b06e673749336aad60acdc5ec","release_hash":"af919b7af379d3edb63faa112dd40a804e2eb49abf832564df5a6e5bb11a4e88","report_id":"erudio-nct04277637","run_id":"c857a80b-4a0f-40fe-8bc8-9538719afaca","schema_version":"5.0","slug":"bgb-11417-101-nct04277637","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"A hematologist described in the sources as reporting their own results reads BGB-11417-101 favorably for its MRD clearance, but remains uncertain about PFS translation. A speaker described as presenting and authoring the results envisages displacing ibrutinib–venetoclax on tolerability grounds; another speaker described as presenting the trial emphasizes response depth. These predictions lack a direct comparison between combinations. Longer follow-up and randomized confirmation are still awaited.","examples":[],"meta_description":"55 sources screened · 133 verified statements (68 from clinicians verified by NPI or staff page) from 27 sources · 13 findings. Updated Nov 20, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-20T04:56:14Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":55},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.","1 cited commentary passage leaves a source question open, such as who was speaking. The report attributes no further than the source shows.","Not yet captured in this edition: a view on the efficacy and tolerability of frontline sonrotoclax plus zanubrutinib in CLL; a remark on early-phase safety and activity in Waldenström macroglobulinemia, including prior BTK inhibitor exposure; a remark on speaker attribution and the relayed nature of first-line sonrotoclax–zanubrutinib commentary; a view on fixed-duration frontline CLL treatment alternatives and their long-term efficacy and safety considerations.","2 passages in 2 sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","47 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 21 sources about other trials or topics are not included.","The sources reviewed for this edition are selected public discussions rather than a representative survey of HCP practice or opinion.","Several speakers are described by their sources as presenting, authoring or reporting the trial. Those descriptions are attributed source information, not independent confirmation of involvement or an external endorsement.","Repeated posts, reposts, interviews and reused excerpts should not be counted as independent HCP endorsements.","Some remarks remain unnamed even when a source title, introduction or participant list names a possible speaker. Those remarks cannot establish ownership of a named view.","No protocol or exact-trial results publication was available among the sources reviewed, limiting checks of cohort definitions, denominators and event attribution.","Different updates use different settings, dose cohorts, MRD thresholds, evaluable populations and follow-up. Their percentages and no-event statements should not be pooled.","Unclear deletion labels and inconsistent recalled timing are left unresolved. They are not corrected to a presumed clinical meaning.","No separate assessment or count of serious adverse events was found in the commentary presented here; high-grade toxicity statements cannot substitute for that endpoint."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":0,"other":0,"podcast":2,"publication":0,"registry":0,"regulatory":0,"x_thread":6,"x_video":1,"youtube":17},"by_evidence_role":{"commentary":27},"count":27,"evidence_window":{"end":"2026-07-21","start":"2021-06-11"},"retrieval_snapshot":"2026-11-19T23:44:54.036681Z","timeline":[{"count":1,"week":"2021-W23"},{"count":1,"week":"2021-W49"},{"count":1,"week":"2022-W05"},{"count":1,"week":"2023-W03"},{"count":1,"week":"2023-W49"},{"count":1,"week":"2024-W20"},{"count":2,"week":"2024-W25"},{"count":1,"week":"2024-W27"},{"count":1,"week":"2024-W31"},{"count":1,"week":"2024-W41"},{"count":1,"week":"2024-W43"},{"count":2,"week":"2024-W48"},{"count":1,"week":"2024-W50"},{"count":2,"week":"2025-W02"},{"count":1,"week":"2025-W05"},{"count":1,"week":"2025-W10"},{"count":1,"week":"2025-W25"},{"count":1,"week":"2025-W26"},{"count":1,"week":"2025-W32"},{"count":2,"week":"2025-W50"},{"count":1,"week":"2025-W51"},{"count":1,"week":"2026-W02"},{"count":1,"week":"2026-W30"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT04277637:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT04277637:context","quote_policy":"short_quote_link_out"},{"id":"openfda:ff684558-e9cb-46de-a8bf-f4d79093df7a:20260925","quote_policy":"short_quote_link_out"},{"id":"openfda:3e08fe23-d70e-424c-bc51-1222e320f902:20260904","quote_policy":"short_quote_link_out"},{"id":"openfda:df12ceb2-5b4b-4ab5-a317-2a36bf2a3cda:20261001","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-b6or56vkmhywvtt2wkcsnbsc-3movfbv6tns2u","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-o6ggjvnj4ze3mnrpnv5oravg-3mbgntun7zb2a","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-plgt5bqnko7dwhzi2436ipuf-3lbvtmrdsh42t","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:067df6","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:11584f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1382392692538175493:4146c6c1-1ed8-4d5e-bdff-41a11db6511e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1614276232023089153:afe02eac-85f3-4864-8761-8620b2236e20","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1790744325145722971:3ea06ca5-79a4-438f-aa76-8907f4907f3d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1804914266962530697:60589197-d96f-453f-8c78-9b1e24ee939c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1810841493533331495:cde976f9-d3a3-4534-8d31-d210fb6c7451","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1811566231763268044:830cd0d7-065f-40b3-a059-fe927165094a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1828055326387495001:75db0527-406a-43d7-9c6a-3d081802a877","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1828417571978084448:daefc60b-1ba7-4b3f-85cd-91e239598a6b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1862185188303819248:b8abb8bf-3ec1-44e3-9efa-a70a05d49daa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1866294952055251106:b5cccf52-603c-4a8d-b918-66d3ccfec427","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1879322544605639152:cb60ddaf-ef33-4ae5-9394-cf535854542c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1897044386254610918:7dc91a8f-ffa5-41cb-abd9-d282522b925d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1902402247218389470:386dedc9-5348-408e-95dc-5e7460a155e3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1933922242762539495:4dc393d4-2378-4ba1-b528-6e3bf2e7296c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1933965082062700707:db76ad25-4355-45d3-8da2-f3a86daa716b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1954271619674771511:19e93db7-1479-4ce9-aaad-e370de9091f7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1998033414906376550:fc19f29b-1706-4123-b504-46e466f8bd5f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1998045008805400841:12ab64ba-2587-426d-b0ce-5771e76ba27d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1998055482292867315:b866f4e0-0a65-4f49-9e50-2b067b18d2dc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1998339332537471079:85b8637c-5a8e-4fe7-9bfd-e7c0b0c7addd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2007014073037103573:3ad13353-af4c-4e32-bc66-3055db47fb64","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2027451171154051147:e19cbdb9-96a9-4f7d-ba42-bcde08c69d73","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061487250290954690:c3e16147-01dd-40e1-a0fa-db7054bbb606","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2065464311753973846:2aa1e878-7def-43ee-a80e-e06a2cd62460","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2069107156163383507:90a69dde-8035-495e-984c-05c0aadfe4d2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2078035066492477573:32ffe8f5-6375-4c8b-91e6-2fc1d18fa262","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2085361971596317159:5c1904e0-caf1-496a-b718-59be7376fe78","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098178553284063462:a757dd49-f1c6-414b-9d6b-d333fd533975","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098200965010600359:2d274cda-3d3d-4c49-8b78-6122eedb1e10","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2106564814764183901:2a853092-9cf9-4e63-8310-ed4d1dfdfe3f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2120651933535141956:013a1bad-c63b-4399-bad4-2e736413cfb0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_video:1897044386254610918","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:3kDeUkZo87U","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:4copxFCwbr8","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:5O3naaO_L1Y","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:BqvDtqyRTcc","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:BwKIW2Kjq50","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:DWvzOijFYlY","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:F86mTZX7ZpM","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:O3XLyZfXGGI","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:QTu6JapDSUA","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:SwoWBnDl5zs","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:TSfueoNs00U","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:gBGeY0xE9Fk","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:hwnqMir_jEk","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:iPH1wFkIrfM","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:lSB9u80QZuM","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:trvArcVEjoc","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:yjporF-JFwk","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:yvrVSZX8EtI","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":3,"linkedin_post":0,"other":0,"podcast":2,"publication":0,"registry":0,"regulatory":0,"x_thread":31,"x_video":1,"youtube":18},"by_evidence_role":{"commentary":55},"count":55,"evidence_window":{"end":"2026-11-11","start":"2021-04-14"},"retrieval_snapshot":"2026-11-19T23:44:54.036681Z","timeline":[{"count":1,"week":"2021-W15"},{"count":1,"week":"2021-W23"},{"count":1,"week":"2021-W49"},{"count":1,"week":"2022-W05"},{"count":1,"week":"2023-W02"},{"count":1,"week":"2023-W03"},{"count":1,"week":"2023-W49"},{"count":1,"week":"2024-W18"},{"count":1,"week":"2024-W20"},{"count":3,"week":"2024-W25"},{"count":1,"week":"2024-W27"},{"count":2,"week":"2024-W28"},{"count":1,"week":"2024-W31"},{"count":2,"week":"2024-W35"},{"count":1,"week":"2024-W41"},{"count":1,"week":"2024-W43"},{"count":2,"week":"2024-W48"},{"count":1,"week":"2024-W50"},{"count":2,"week":"2025-W02"},{"count":1,"week":"2025-W03"},{"count":1,"week":"2025-W05"},{"count":2,"week":"2025-W10"},{"count":1,"week":"2025-W12"},{"count":2,"week":"2025-W24"},{"count":1,"week":"2025-W25"},{"count":1,"week":"2025-W26"},{"count":1,"week":"2025-W32"},{"count":4,"week":"2025-W50"},{"count":1,"week":"2025-W51"},{"count":2,"week":"2026-W01"},{"count":1,"week":"2026-W02"},{"count":1,"week":"2026-W09"},{"count":1,"week":"2026-W23"},{"count":1,"week":"2026-W24"},{"count":2,"week":"2026-W26"},{"count":1,"week":"2026-W29"},{"count":1,"week":"2026-W30"},{"count":1,"week":"2026-W32"},{"count":2,"week":"2026-W37"},{"count":1,"week":"2026-W40"},{"count":1,"week":"2026-W46"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":5,"linkedin_post":0,"other":0,"podcast":24,"publication":0,"registry":0,"regulatory":0,"x_thread":9,"x_video":1,"youtube":94}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":["Beqalzi"],"label":"sonrotoclax","slug":"sonrotoclax"},{"brand_names":["Brukinsa"],"label":"zanubrutinib","slug":"zanubrutinib"},{"brand_names":["Gazyva"],"label":"obinutuzumab","slug":"obinutuzumab"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Mature B-cell malignancies","slug":"mature-b-cell-malignancies"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"BGB-11417-101","aliases":["BGB-11417-101","Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies","A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies"],"brief_title":"Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Mature B-Cell Malignancies"],"display_condition":"mature B-cell malignancies","display_interventions":[["sonrotoclax"],["sonrotoclax","zanubrutinib"],["sonrotoclax","zanubrutinib","obinutuzumab"]],"enrollment":{"count":437,"type":"ACTUAL"},"interventions":[{"name":"Sonrotoclax","synonyms":["BGB-11417"],"type":"DRUG"},{"name":"Zanubrutinib","synonyms":["BGB-3111"],"type":"DRUG"},{"name":"Obinutuzumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT04277637","official_title":"A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE1"],"primary_completion_date":{"date":"2027-05-31","type":"ESTIMATED"},"primary_endpoints":[{"measure":"Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)","timeFrame":"Up to 30 days after the last dose of study drug, an average of 18 months"},{"measure":"Number of Participants Experiencing Serious Adverse Events (SAEs)","timeFrame":"Up to 30 days after the last dose of study drug, an average of 18 months"},{"measure":"Number of Participants Experiencing Adverse Events (AEs) leading to discontinuation of Sonrotoclax","timeFrame":"Up to 30 days after the last dose of study drug, an average of 18 months"},{"measure":"Part 1, Part 3: Maximum Tolerated Dose (MTD) of Sonrotoclax","timeFrame":"Up to approximately 2 months"},{"measure":"Part 1, Part 3, Part 5: RP2D of Sonrotoclax","timeFrame":"Day 1 to last dose of study drug, an average of 18 months"},{"measure":"Part 1, Part 3, Part 5: Number of participants experiencing tumor lysis syndrome (TLS) relevant events","timeFrame":"Up to 30 days after the last dose of study drug, an average of 18 months"},{"measure":"Part 1, Part 3, Part 5: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs","timeFrame":"Up to approximately 2 months"}],"registered_date":{"date":"2020-02-20","type":"ACTUAL"},"registry_last_updated":"2026-06-22","registry_url":"https://clinicaltrials.gov/study/NCT04277637","short_name":"BGB-11417-101","short_name_basis":"canonical_name","sponsor":"BeOne Medicines","start_date":{"date":"2020-03-24","type":"ACTUAL"},"study_design":"interventional, non randomized, parallel, phase1","study_ids":[{"id":"BGB-11417-101","type":"sponsor_study_id"},{"id":"2024-515592-35-00","type":"ctis"},{"id":"2020-004641-37","type":"eudract_number"}],"study_type":"INTERVENTIONAL"}}}